Concepts (98)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematology | 1 | 2020 | 99 | 0.660 |
Why?
|
| Education, Distance | 1 | 2020 | 100 | 0.650 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 705 | 0.600 |
Why?
|
| Fellowships and Scholarships | 1 | 2020 | 411 | 0.540 |
Why?
|
| Medical Oncology | 3 | 2022 | 1465 | 0.530 |
Why?
|
| Hospitals, Public | 1 | 2016 | 60 | 0.520 |
Why?
|
| Time-to-Treatment | 1 | 2016 | 307 | 0.440 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 625 | 0.420 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 700 | 0.410 |
Why?
|
| Rectal Neoplasms | 2 | 2020 | 1240 | 0.390 |
Why?
|
| Pandemics | 1 | 2020 | 1610 | 0.370 |
Why?
|
| Colorectal Neoplasms | 4 | 2024 | 3707 | 0.200 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 89 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 83 | 0.160 |
Why?
|
| Minocycline | 1 | 2019 | 189 | 0.150 |
Why?
|
| Texas | 2 | 2020 | 6447 | 0.140 |
Why?
|
| Learning | 1 | 2020 | 431 | 0.140 |
Why?
|
| Hepatitis B | 1 | 2019 | 275 | 0.130 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 1437 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 513 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 907 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 900 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2019 | 549 | 0.110 |
Why?
|
| Fatigue | 1 | 2019 | 1279 | 0.110 |
Why?
|
| Disease Progression | 1 | 2024 | 6855 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 3408 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 354 | 0.100 |
Why?
|
| Virus Diseases | 1 | 2016 | 392 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 5923 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 914 | 0.100 |
Why?
|
| Quality of Health Care | 1 | 2016 | 619 | 0.090 |
Why?
|
| Ovariectomy | 1 | 2012 | 371 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2023 | 2330 | 0.090 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 14616 | 0.090 |
Why?
|
| Disease Management | 1 | 2016 | 1089 | 0.090 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 3240 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 855 | 0.080 |
Why?
|
| Research Design | 1 | 2016 | 1569 | 0.080 |
Why?
|
| Metformin | 1 | 2012 | 393 | 0.080 |
Why?
|
| Time Factors | 3 | 2019 | 13021 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 598 | 0.070 |
Why?
|
| Neoplasms | 3 | 2019 | 15919 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2155 | 0.070 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 3181 | 0.070 |
Why?
|
| Humans | 13 | 2024 | 270802 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 14012 | 0.050 |
Why?
|
| Male | 7 | 2024 | 128397 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 1417 | 0.050 |
Why?
|
| Palliative Care | 1 | 2012 | 2178 | 0.040 |
Why?
|
| Female | 7 | 2022 | 148967 | 0.040 |
Why?
|
| Prevalence | 2 | 2019 | 3402 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 58 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2023 | 557 | 0.040 |
Why?
|
| Mass Screening | 2 | 2019 | 1549 | 0.040 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 58 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2019 | 76 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2019 | 96 | 0.040 |
Why?
|
| Nursing Staff, Hospital | 1 | 2019 | 74 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 279 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 272 | 0.040 |
Why?
|
| Curriculum | 1 | 2022 | 919 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2024 | 5310 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2012 | 4795 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 1089 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 409 | 0.030 |
Why?
|
| Aged | 5 | 2024 | 73382 | 0.030 |
Why?
|
| Radiation Oncology | 1 | 2020 | 558 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 1335 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 13417 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 2588 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4498 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 1253 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 2027 | 0.020 |
Why?
|
| Sarcoma | 1 | 2002 | 1838 | 0.020 |
Why?
|
| Middle Aged | 5 | 2019 | 90347 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 2388 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2023 | 3557 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 3109 | 0.020 |
Why?
|
| ras Proteins | 1 | 2012 | 804 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 22225 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 5231 | 0.020 |
Why?
|
| Adult | 3 | 2019 | 81997 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 4775 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1401 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4328 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 1335 | 0.010 |
Why?
|
| Survival Rate | 2 | 2012 | 12527 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 2618 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6255 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2019 | 33741 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 16669 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2012 | 39832 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 32743 | 0.010 |
Why?
|
| Nephrectomy | 1 | 2002 | 798 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 17900 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 31008 | 0.010 |
Why?
|
| Mutation | 1 | 2012 | 15911 | 0.010 |
Why?
|
| Prognosis | 1 | 2002 | 22481 | 0.000 |
Why?
|